US and UK Sign Zero-Tariff Deal on Drugs.
The United Kingdom and the United States have reached a key bilateral deal that will guarantee zero tariffs on UK drug exports being sold in the US market.
The Terms of the Pact
Under the terms of the agreement, the UK has agreed to raise spending on drugs through the public health system. This move secures that tariffs on these crucial goods will be held at nothing for a period of 36 months.
This development is in response to earlier statements to significantly raise import taxes on patented drug imports, with figures floated as high as double the cost.
"This agreement between the United Kingdom bolsters the global environment for cutting-edge drugs and establishes long-overdue balance to American-British drug exports," an announcement noted.
Economic Significance
Pharmaceuticals are one of the the United Kingdom's largest exports to the US, which is clearly the largest destination for leading UK drugmakers.
Trade data reveal that in the year prior to the third quarter, the UK sold medicines worth £11.1bn to the US. This amount accounted for nearly one-fifth of total UK exports in that period.
"This agreement protects employment, stimulates capital expenditure and paves the way for the UK to become a global hub for life sciences," a government official stated.
Key NHS Changes
The deal involves several specific changes from the UK:
- Revised Affordability Limit: The UK will raise the cost ceiling at which it deems new treatments to be prohibitively costly by 25%.
- Increased NHS Spending: There is a target to double total health service expenditure on medicines from 0.3% of the national economy to 0.6% over the following ten-year period.
- Payback Limit: The percentage pharmaceutical firms must return to the NHS to control costs will be limited at 15%. Last year, refunds were more than 20%.
Broader Context
The pact follows a protracted row between the sector and the British authorities over medicine costs and NHS adoption.
This friction were intensified by arguments that US customers were paying several times more for the equivalent treatments than consumers in the other developed nations.
Recently, several significant pharmaceutical investments in the UK have been halted or cancelled, while major expansions have been directed toward US facilities.
A senior figure acknowledged that the NHS must invest a greater share on medicines, noting that its expenditure on drugs had decreased as a share of its overall budget over the previous ten-year period.
